Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FBLG 
FibroBiologics, Inc. Common Stock (FBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: FBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.25
1 Year Target Price $10.25
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.51% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.74M USD | Price to earnings Ratio - | 1Y Target Price 10.25 |
Price to earnings Ratio - | 1Y Target Price 10.25 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 0.53 - 3.89 | Updated Date 09/15/2025 |
52 Weeks Range 0.53 - 3.89 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -88.11% | Return on Equity (TTM) -559.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24668426 | Price to Sales(TTM) - |
Enterprise Value 24668426 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 41889100 | Shares Floating 32066138 |
Shares Outstanding 41889100 | Shares Floating 32066138 | ||
Percent Insiders 19.57 | Percent Institutions 12.25 |
Upturn AI SWOT
FibroBiologics, Inc. Common Stock
Company Overview
History and Background
FibroBiologics, Inc. is a clinical-stage biotechnology company focused on the development of fibroblast-based therapies for chronic diseases with unmet medical needs. Founded in 2012, the company is based in Houston, Texas.
Core Business Areas
- Fibroblast-Based Therapies: Development and commercialization of fibroblast-based therapies for various conditions, including degenerative disc disease, cancer and wound healing.
Leadership and Structure
Dr. Tom Ichim is the Chief Executive Officer. The company has a scientific advisory board comprising experts in regenerative medicine and related fields. Organizational structure is typical of a clinical-stage biotech, with research, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- CybroCell: A fibroblast-based therapy for degenerative disc disease. Currently in clinical trials. Market share is not applicable as it is still in clinical trials. Competitors include companies developing alternative treatments for degenerative disc disease, such as surgical interventions and pain management therapies.
- T-cell Fibroblasts: Fibroblasts engineered to attack cancer cells. Pre-clinical stage. Market share is not applicable as it is still in pre-clinical development. Competitors include companies developing cancer therapies, such as chemotherapy, immunotherapy and targeted therapies.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by increasing demand for therapies that can repair or replace damaged tissues and organs. There's a growing interest in cell-based therapies.
Positioning
FibroBiologics is positioned as a developer of novel fibroblast-based therapies. Its competitive advantage lies in its proprietary fibroblast technology platform.
Total Addressable Market (TAM)
The regenerative medicine market is projected to reach hundreds of billions USD. FibroBiologics is positioned to capture a portion of this market with its fibroblast-based therapies, dependent on successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary fibroblast technology platform
- Experienced management team
- Focus on unmet medical needs
- Promising pre-clinical and clinical data
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercialized products
- Relatively small team
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new indications
- Accelerated regulatory pathways for regenerative medicine therapies
- Increased awareness of the potential of fibroblast-based therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Difficulties in scaling up manufacturing
Competitors and Market Share
Key Competitors
- DiscGenics (Private)
- Mesoblast (MESO)
- Vertex Pharmaceuticals (VRTX)
Competitive Landscape
FibroBiologics competes with companies developing regenerative medicine therapies, traditional pharmaceuticals, and surgical interventions. The advantage is the potential of a fibroblast-based therapy. Disadvantages are small size and cash burn.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited to advancements in pre-clinical and clinical programs.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its fibroblast-based therapies. Analyst estimates are not widely available due to the company's early stage.
Recent Initiatives: Focusing on clinical trial initiation for CybroCell for degenerative disc disease and continued pre-clinical research into other applications.
Summary
FibroBiologics is a clinical-stage biotech company with a novel fibroblast technology platform. It is focused on developing therapies for unmet medical needs, particularly degenerative disc disease and cancer. Success depends on clinical trials, regulatory approval and commercialization. Its small size and cash burn are risk factors to be followed closely. It requires additional funding to get approved therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Publicly available scientific literature
- Market research reports
- Third party financial data providers
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data is limited due to company being private. The analysis is based on available information and general knowledge of the industry.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FibroBiologics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-01-31 | Founder, Chairperson & CEO Mr. Peter O'Heeron | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.fibrobiologics.com |
Full time employees 13 | Website https://www.fibrobiologics.com | ||
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.